Molecule Details
| InChIKey | IENZQIKPVFGBNW-UHFFFAOYSA-N |
|---|---|
| Compound Name | Prazosin |
| Canonical SMILES | COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC |
| Clinical Status | Clinical Multi-Target |
| Targets (Human+Pathogen) | 11 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.19 |
| Source | BindingDB;ChEMBL;TTD_MultiTarget |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB00457 |
|---|---|
| Drug Name | Prazosin |
| CAS Number | 19216-56-9 |
| Groups | approved investigational |
| ATC Codes | C02LE01 C02CA01 |
| Description | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-tra... |
Categories: Adrenergic Antagonists Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Alpha-Adrenoreceptor Antagonists and Diuretics Antiadrenergic Agents, Peripherally Acting Antihypertensive Agents Antihypertensive Agents Indicated for Hypertension BCRP/ABCG2 Substrates Cardiovascular Agents Heterocyclic Compounds, Fused-Ring Hypotensive Agents OCT1 inhibitors OCT1 substrates OCT2 Substrates P-glycoprotein inhibitors P-glycoprotein substrates Peripheral alpha-1 blockers Quinazolines Vasodilating Agents
Cross-references: BindingDB: 29568 ChEBI: 8364 CHEMBL2 ChemSpider: 4724 Drugs Product Database (DPD): 11108 Guide to Pharmacology: 503 IUPHAR: 503 C07368 D08411 PDB: XRA PharmGKB: PA451093 PubChem:4893 PubChem:46508594 RxCUI: 8629 Therapeutic Targets Database: DAP000300 Wikipedia: Prazosin ZINC: ZINC000095616601
Target Activities (11)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P25100 | ADRA1D | Homo sapiens | Human | PF00001 | 9.5 | Ki | ChEMBL;BindingDB |
| P28221 | HTR1D | Homo sapiens | Human | PF00001 | 9.5 | Ki | ChEMBL;BindingDB |
| P35368 | ADRA1B | Homo sapiens | Human | PF00001 | 9.4 | Ki | ChEMBL;BindingDB |
| P35348 | ADRA1A | Homo sapiens | Human | PF00001 | 9.2 | Ki | ChEMBL;BindingDB |
| P18505 | GABRB1 | Homo sapiens | Human | PF02931 PF02932 | 9.1 | pIC50 | TTD_MultiTarget |
| P16083 | NQO2 | Homo sapiens | Human | PF02525 | 8.1 | IC50 | ChEMBL;BindingDB |
| P18825 | ADRA2C | Homo sapiens | Human | PF00001 | 7.3 | Ki | ChEMBL;BindingDB |
| P18089 | ADRA2B | Homo sapiens | Human | PF00001 | 7.0 | Ki | ChEMBL;BindingDB |
| P08913 | ADRA2A | Homo sapiens | Human | PF00001 | 6.6 | Ki | ChEMBL;BindingDB |
| P47898 | HTR5A | Homo sapiens | Human | PF00001 | 6.1 | Ki | ChEMBL |
| Q9ULZ9 | MMP17 | Homo sapiens | Human | PF00045 PF00413 PF01471 | Clinical | TTD_MultiTarget | TTD_MultiTarget |
DrugBank Target Actions (14)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P02763 | P02763 | Alpha-1-acid glycoprotein 1 | substrate | carriers |
| P25100 | ADRA1D | Alpha-1D adrenergic receptor | antagonist | targets |
| P35348 | ADRA1A | Alpha-1A adrenergic receptor | antagonist | targets |
| P35368 | ADRA1B | Alpha-1B adrenergic receptor | antagonist | targets |
| P08913 | ADRA2A | Alpha-2A adrenergic receptor | binder | targets |
| P18089 | ADRA2B | Alpha-2B adrenergic receptor | binder | targets |
| Q12809 | KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | inhibitor | targets |
| O15245 | SLC22A1 | Solute carrier family 22 member 1 | inhibitor | transporters |
| O75751 | SLC22A3 | Solute carrier family 22 member 3 | inhibitor | transporters |
| P08183 | ABCB1 | ATP-dependent translocase ABCB1 | inhibitor | transporters |
| P08183 | ABCB1 | ATP-dependent translocase ABCB1 | modulator | transporters |
| O15245 | SLC22A1 | Solute carrier family 22 member 1 | substrate | transporters |
| P08183 | ABCB1 | ATP-dependent translocase ABCB1 | substrate | transporters |
| Q9UNQ0 | ABCG2 | Broad substrate specificity ATP-binding cassette transporter ABCG2 | substrate | transporters |